The company said, “We expect the cash, cash equivalents, and investments on December 31, 2024, will enable us to fund operations into 2027 beyond topline Phase 3 data for DURAVYU in wet AMD expected in 2026. Accordingly, we currently have no plans to access the equity capital markets in 2025.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EYPT:
- Eyepoint Pharma (EYPT) Q4 Earnings Cheat Sheet
- EyePoint Pharmaceuticals: Buy Rating Backed by Promising Duravyu Phase 2 Results and Growth Potential in Undervalued Market
- EyePoint Pharmaceuticals: An Undervalued Opportunity Amid Market Overreaction and Financing Concerns
- Collegium appoints Nancy Lurker to board of directors
- EyePoint announces Phase 2 VERONA trial met primary endpoint